Back

What is optimal dual anti-platelet therapy duration after percutaneous coronary intervention?

European Heart Journal - Cardiovascular Pharmacotherapy

9 November 2023
Organised by: Logo
Read full article
ESC Journals

Contributors

Hiroki Shiomi
Hiroki Shiomi

Author

Kyoto University Kyoto , Japan

Koji Hasegawa
Koji Hasegawa

Author

National Hospital Organization Kyoto Medical Centre Kyoto , Japan

Koh Ono
Koh Ono

Author

You may be interested in
thumbnail
Congress Presentation
When should prolonged antiplatelet regimens be considered?
26 August 2023
thumbnail
Congress Presentation
Single vs dual antiplatelet therapy after spontaneous coronary artery dissection
21 March 2026
thumbnail
Congress Presentation
Optimizing post-PCI therapy: ticagrelor, prasugrel, clopidogrel, and cilostazol reduce early MACE
21 March 2026
thumbnail
Congress Presentation
Perioperative risk and benefit of antiplatelet therapy in patients undergoing non-cardiac surgery within 1 year after percutaneous coronary intervention with second-generation drug-eluting stents.
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources